Literature DB >> 28571022

Therapeutic Use Exemptions.

David Gerrard, Andrew Pipe.   

Abstract

The introduction, in 2004, of the World Anti-Doping Code and a standardized "prohibited list" of substances and methods proscribed in sport represented a consistent, international response to the escalating challenge of drug misuse in contemporary sport. Simultaneously, it was recognized that athletes experiencing illness or injury might legitimately require the use of "prohibited" medications or procedures, and the concept of the "therapeutic use exemption" (TUE) was introduced. The mechanisms of the TUE process are carefully defined and described in a specific WADA "international standard" (IS). As a consequence, anti-doping organizations (ADOs) were empowered to establish "Therapeutic Use Exemption Committees" (TUECs) whose membership and responsibilities were clearly delineated in the IS, and to whom an athlete and treating physician(s) could make appropriate application for a TUE. A careful review of such an application by a TUEC panel of physicians might allow permission for an otherwise prohibited course of treatment, provided that appropriate criteria had been met. Sport physicians have a clear responsibility to ensure accurate and complete documentation of the clinical circumstances requiring a TUE when completing such applications. Typically, applications for consideration by TUECs are forwarded to a national ADO, but depending on an applicant's level of competition, it may become necessary to involve an international federation or major event organization (e.g., International Olympic Committee, or Commonwealth Games Federation). Such organizations may receive, review, and grant TUEs specific to the competitions over which they preside. Increasingly, there is recognition of TUEs granted by other ADOs. However, this is not always the case; in certain circumstances, the decisions of other TUECs to grant or deny an application may be appealed. The advent of the TUE process ensures that an athlete with a genuine medical condition that necessitates the use of a prohibited substance or procedure can apply for permission to use such treatments and is not denied access to competition or training.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28571022     DOI: 10.1159/000460700

Source DB:  PubMed          Journal:  Med Sport Sci        ISSN: 0076-6070


  4 in total

Review 1.  The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.

Authors:  L Di Luigi; F Pigozzi; P Sgrò; L Frati; A Di Gianfrancesco; M Cappa
Journal:  J Endocrinol Invest       Date:  2019-11-16       Impact factor: 4.256

2.  Engaging community pharmacists to eliminate inadvertent doping in sports: A study of their knowledge on doping.

Authors:  Nontharit Voravuth; Eng Wee Chua; Tuan Mazlelaa Tuan Mahmood; Ming Chiang Lim; Sharifa Ezat Wan Puteh; Nik Shanita Safii; Jyh Eiin Wong; Ahmad Taufik Jamil; Jamia Azdina Jamal; Ahmad Fuad Shamsuddin; Adliah Mhd Ali
Journal:  PLoS One       Date:  2022-06-10       Impact factor: 3.752

3.  Drugs in sport: The curse of doping and role of pharmacologist.

Authors:  Dhruv Mahendru; Subodh Kumar; Ajay Prakash; Bikash Medhi
Journal:  Indian J Pharmacol       Date:  2019 Jan-Feb       Impact factor: 1.200

Review 4.  Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.

Authors:  Matti L Gild; Mark Stuart; Roderick J Clifton-Bligh; Audrey Kinahan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.